Yiheng Capital Management L.P. Purchases 100,000 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Yiheng Capital Management L.P. raised its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 16.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 700,098 shares of the company's stock after purchasing an additional 100,000 shares during the period. Denali Therapeutics accounts for 0.5% of Yiheng Capital Management L.P.'s portfolio, making the stock its 11th largest holding. Yiheng Capital Management L.P. owned 0.49% of Denali Therapeutics worth $14,268,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP grew its holdings in Denali Therapeutics by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company's stock valued at $312,491,000 after buying an additional 903,683 shares during the last quarter. FMR LLC boosted its position in shares of Denali Therapeutics by 3,234.3% in the third quarter. FMR LLC now owns 7,831,378 shares of the company's stock valued at $228,128,000 after acquiring an additional 7,596,508 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Denali Therapeutics by 63.2% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company's stock worth $109,223,000 after acquiring an additional 1,451,770 shares during the last quarter. Principal Financial Group Inc. increased its position in Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock worth $36,076,000 after acquiring an additional 149,939 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in Denali Therapeutics by 1.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,028,462 shares of the company's stock valued at $20,960,000 after purchasing an additional 12,652 shares during the last quarter. Institutional investors own 92.92% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

DNLI has been the topic of several research reports. William Blair restated an "outperform" rating on shares of Denali Therapeutics in a report on Friday, February 28th. Morgan Stanley began coverage on Denali Therapeutics in a report on Friday, March 7th. They issued an "overweight" rating and a $33.00 price target for the company. Robert W. Baird started coverage on Denali Therapeutics in a report on Tuesday, January 7th. They set an "outperform" rating and a $31.00 price objective on the stock. The Goldman Sachs Group cut their target price on Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating on the stock in a research note on Tuesday, January 7th. Two equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Denali Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.20.

Insider Activity

In other Denali Therapeutics news, Director Vicki L. Sato sold 3,080 shares of the firm's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the sale, the director now owns 107,976 shares in the company, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Ryan J. Watts sold 29,266 shares of the business's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $591,758.52. Following the completion of the transaction, the chief executive officer now directly owns 260,721 shares of the company's stock, valued at approximately $5,271,778.62. This represents a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 47,940 shares of company stock worth $973,442. 7.90% of the stock is owned by corporate insiders.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI traded down $0.64 during mid-day trading on Tuesday, hitting $14.12. 936,016 shares of the stock were exchanged, compared to its average volume of 998,756. Denali Therapeutics Inc. has a twelve month low of $14.01 and a twelve month high of $33.33. The stock's fifty day simple moving average is $19.59 and its two-hundred day simple moving average is $23.54. The company has a market cap of $2.05 billion, a P/E ratio of -5.12 and a beta of 1.46.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.08. As a group, equities research analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.